Autoinflammatory & rare systemic diseases
Effects of interleukin-1 antagonists on de novo and pre-existing damage in patients with familial Mediterranean fever
Authors' conclusion
We evaluated change in damage accrual while using IL-1 antagonists in patients with FMF.
Study context
- Population
- Patients with FMF fulfilling Eurofever and Tel-Hashomer criteria, treated with interleukin (IL-1) antagonists
- Participants
- 111 patients
- Exposure
- No damage vs Pre-existing damage vs De novo damage
- Outcome
- Damage (ADDI; Modified ADDI (mADDI) excluding chronic musculoskeletal pain) under IL-1 antagonist treatment
Main finding
As reported in the abstract
Damage according to mADDI
Patients developing de novo damage under IL-1 antagonists (one musculoskeletal, one reproductive)
2
Patients with worsening of damage while using IL-1 antagonists
5
Median duration of treatment (months)
45
Observational data: associations, not effects.
Further findings
Damage domains
- Damage commonly observed at musculoskeletal, renal and reproductive domains
Factors associated with de novo damage
- De novo damage with IL-1 antagonist treatment associated with acute phase protein levels
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Effects of interleukin-1 antagonists on de novo and pre-existing damage in patients with familial Mediterranean fever. Clin Exp Rheumatol. Published 29 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →